The Latest Cardiac and Vascular News
Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low. Adjusted for constant currency, Core non-COVID 2022 product sales were within 5% of that achieved in 2021 and greater than 30% increased from pre-pandemic 2019 PRINCETON, N.J., Jan. 31, 2023 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment […]
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that the company has raised bridge financing to support its 2023 objectives. Endeavour Vision and RiverVest Venture […]
SHENZHEN, China, Jan. 31, 2023 /PRNewswire/ — Mindray, a global leading medical device solutions provider, today announces the launch of next-generation BeneHeart series defibrillators, the BeneHeart D60 and D30. The new BeneHeart defibrillators aim to raise the standards for resuscitation with superior reliability, expert comprehensive diagnosis and monitoring tools, and introduce a […]
~ Preliminary fourth quarter 2022 sales increase of 18% to 19% versus 2021 ~ ~ Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call ~ PLANO, Texas, Jan. 30, 2023 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource manufacturer, announces preliminary financial […]
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2022 NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2022. Financial Highlights Revenue from royalties […]
The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – January 31, 2023 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a marketing authorisation application (MAA) to the European […]
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion and Operational and Financial Excellence Underscores Sarissa’s Misguided Proxy Contest – […]
Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not Recommended SANTA CLARA, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today […]
Trial will evaluate the safety and effectiveness of the AtriCure AtriClip® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA). The study was led by Dr. Marianne Brodmann (Radcliffe Cardiology, Graz, Austria). This sub-analysis compared their PRELUDE-BTK subset to a consecutive […]
